Carisma Therapeutics Inc expected to post a loss of 43 cents a share - Earnings Preview

Carisma Therapeutics

07/05/2024 16:54

* Carisma Therapeutics Inc  CARM.OQ   CARM.O  is expected
to show
a rise in quarterly revenue when it reports  results on May 9
(estimated) for the period ending March 31 2024
    * The Cambridge Massachusetts-based  company is expected to
report
a 35.7% increase in revenue to $4.4 million from $3.24 million a
year ago, according to the mean estimate from 3 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for Carisma Therapeutics Inc
is
for a loss of 43 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Carisma
Therapeutics Inc is $9.50​, above​ its last closing price
of $1.60. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023              -0.55      -0.52     Beat    5.9
 Sep. 30 2023  -0.56       -0.57      -0.53     Beat    7
 Jun. 30 2023  -0.60       -0.60      -0.49     Beat    17.9​
 Mar. 31 2023  -0.89       -0.89      -1.93     Missed  -116.9
 ​​Dec.        -2.20       -2.20      -0.80     Beat    63.6
 31 2022                                                
 Sep. 30 2022  -1.60       -1.60      2.00      Beat    225​
 Jun. 30 2022  -2.60       -2.60      -3.20     Missed  -23.1
 Mar. 31 2022  -1.97       -2.00      0.00      Beat    100
 This summary was machine generated May 7 at 15:54 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)